Accolade — Q4 2024 Earnings Presentation
12 slides from Accolade's earnings presentation, Apr 25, 2024
Slide 1: F4Q24 Earnings Presentation
Lf Accolade April 25, 2024 NASDAQ: ACCD Accolade Inc. F4Q24 Earnings Presentation
Slide 2: Forward-looking statements and non-GAAP disclaimer
This presentation contains “forward-looking statements” –that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such ‘‘anticipate,’’ ‘‘b
Slide 3: F4Q24 Earnings Presentation
Lf Accolade April 25, 2024 NASDAQ: ACCD Accolade Inc. F4Q24 Earnings Presentation
Slide 4: Quarter and fiscal year ended 2/29/2024 results
Quarter ended Fiscal Year ended 2/29/2024 2/29/2024 Revenue $124.8M $414.3M Adjusted EBITDA $18.5M ($7.5)M Adjusted Gross 54.2% 47.6% Margin 3
Slide 5: Guidance for quarter and fiscal year ending 2025
Quarter ending Fiscal Year ending 5/31/2024 2/28/2025 Revenue $103M - $106M $480M - $500M Adjusted EBITDA $(9 – 12)M $15M - $20M 4
Slide 6: FY25P Quarterly Model on Full Year Guide of $480M-500M Revenue
FY25P Quarterly Model on Full Year Guide of $480M-500M Revenue ~$156.5M ~$113M ~$116M ~$104.5M FY22 FY23 FY24 FY25P FY22 FY23 FY24 FY25P FY22 FY23 FY24 FY25P FY22 FY23 FY24 FY25P F1Q F2Q F3Q F4Q Total Revenue Ex. Savings PG's Savings PGs 5
Slide 7: Cadence on FY25P Quarterly Model and 3-4% Adjusted EBITDA
Cadence on FY25P Quarterly Model on Full Year Guide $480M-$500M Revenue and 3-4% Adjusted EBITDA FY24 cadence for full year total of $(7.5)M ~$34M FY25 cadence outlook for full year guide of 3-4% of revenue $13.9 M $(5-8)M $(8.8)M $(9-12)M $(12.6)M FY24 FY25P FY24 FY25P FY24 FY25P F1Q F2Q F2H 6
Slide 8: Revenue mix: usage-based, access fees, platform-connected revenue
$500 $480M-$500M $60 $414M ~30-35% $50 $400 $363M 27% $40 $310M 22% $300 15% millions millions $30 $200 $20 85% 78% 73% 65-70% $100 $10 $- $- FY22 FY23 FY24 FY25P Usage-Based Fees (left axis) - primary care visit fees, EMO case-rate consultations, usage-based TPE Access Fees (left axis) - PEPM-based
Slide 9: B2B Growth Drivers $480-$500M
B2B Growth Drivers $480-$500M $414M millions FY24 Revenue Terminations FY24 ARR1 FY25 ARR1 & Incremental Incremental FY25 Revenue Other In-Year Platform- Direct-to- Revenue Connected Consumer Revenue 1 Annual recurring revenue (ARR) is a performance measure representing the estimated annualized gros
Slide 10: Sample customer ~50% increase in revenue and PMPM
Sample customer ~ 50% increase in revenue $ and PMPM over multi-year period Example customer demonstrating expansion of platform-enabled revenue through attachment of additional offerings, and incremental usage-based revenue $20 $12 $10 Revenues PMPM $8 $- $6 FY20 FY21 FY22 FY23 FY24 TPE eVPC EMO Na
Slide 11: Up to 50% incremental revenue lift in customer base
Up to 50% incremental revenue lift in customer base at target attachment and utilization rates ~$20 PEPM Advocacy Expert Medical Virtual Primary Ecosystem New Opportunities Opinion Care 10 Note: Chart is for illustrative purposes only.
Slide 12: Accolade
Accolade PERSONALIZED HEALTHCARE